US9447077 — Crystalline pharmaceutical and methods of preparation and use thereof
Method of Use · Assigned to Sarcode Bioscience Inc · Expires 2029-04-15 · 3y remaining
What this patent protects
This patent discloses novel crystalline polymorphic forms of a compound that inhibits LFA-1 and methods of preparing and using it to treat LFA-1 mediated diseases.
USPTO Abstract
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Drugs covered by this patent
- Xiidra (LIFITEGRAST) · Bausch Health
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1900 |
— | Xiidra |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.